德纳维制药Z-1018试验显示注射后不良反应低于Shingrix

美股速递
Aug 21

德纳维制药宣布,在Z-1018临床试验中,其疫苗产品显示出比Shingrix更低的预期局部和全身注射后不良反应。这一试验结果表明,德纳维制药的疫苗候选产品在安全性方面可能具有优势,注射后引发的局部反应和全身性反应均较Shingrix为低。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10